Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease

Movement Disorders

Volumn 13, Issue 5, 1998, Pages 788-797

  Ryoo, Han L ^a   Pierrotti, Dylan ^b   Joyce, Jeffrey N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Basal ganglia; Levodopa; Mesolimbic; Nigrostriatal; Parkinson's disease; Receptor autoradiography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; IODINE 125; RADIOLIGAND; TYROSINE 3 MONOOXYGENASE; DRD3 PROTEIN, HUMAN;

ADULT; AGED; AMINE TRANSPORT; ANTERIOR HYPOTHALAMUS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; ISOTOPE LABELING; LATERAL HYPOTHALAMUS; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NIGRONEOSTRIATAL SYSTEM; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; AUTORADIOGRAPHY; BRAIN MAPPING; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOASSAY;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BRAIN MAPPING; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TYROSINE 3-MONOOXYGENASE;

EID: 0031593727     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130506     Document Type: Article

References (18)

1. 2 dopamine receptors. In: Waddington JL, ed. Neuroscience and Psychopharmacology: D1:D2 Dopamine Receptor Interactions. San Diego, CA: Academic Press, 1993:1-21.
2. 2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 1997;16:375-384.
3. 2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994;91:11271-11275.
4. 3 receptors in schizophrenics were decreased by antipsychotics. Arch Gen Psychiatry 1997;54:225-232.
5. Adler CH, Sethi KD, Hauser R, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
6. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
7. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995;45(suppl):225-230.
8. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49(suppl 1):S58-S62.
9. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984;99:167-175.
10. Seeman P, Bzowej NH, Guan HC, et al. Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15.
11. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW. Dopamine D-2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 1986;19:487-492.
12. Joyce JN. Differential response of striatal dopamine receptor subtypes and cholinergic muscarinic receptors to the loss of dopamine: III. Effects in Parkinson's disease. Brain Res 1993;600:156-160.
13. 125I]epidepride binding to dopamine D-2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther 1991;257:1253-1263.
14. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. Dopamine receptor changes differ between Parkinson's and Alzheimer's disease with parkinsonism: a receptor autoradiographic study. Neuropsychopharmacology. In press.
15. 3) as a target for neuroleptics. Nature 1990;347:146-151.
16. Joyce JN, Sapp DW, Marshall JF. Human striatal dopamine receptors are organized in compartments. Proc Natl Acad Sci USA 1986;83:8002-8006.
17. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 1995;92:1719-1723.
18. 3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 1996;214:75-78.